SCHEMBL6154904

SCHEMBL6154904

C[S+]([O-])c1ccc(-c2sc(NCc3ccccc3)nc2-c2ccc(F)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 8/20 0.51
PTGS1 P23219 1/20 0.51
ROCK2 O75116 1/20 0.49
GSK3B P49841 1/20 0.49
MAPK14 Q16539 5/20 0.45
TGFBR1 P36897 4/20 0.45
ACHE P22303 1/20 0.43
PTGDR2 Q9Y5Y4 1/20 0.42
NR1H4 Q96RI1 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
GAA P10253 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
HSD17B10 Q99714 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
XIAP P98170 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL216750 0.83 PTGS2 (0.69) PTGS2PTGS1
SCHEMBL8797135 0.81 MAPT (0.45) PTGS2PTGS1ACHEKDM4EALDH1A1
SCHEMBL7841561 0.80 PTGS2 (0.71) PTGS2PTGS1ROCK2GSK3B
SCHEMBL27605219 0.79 ROCK2 (0.50) PTGS2PTGS1ROCK2GSK3BMAPK14
SCHEMBL11368657 0.77 PTGS2 (0.65) PTGS2PTGS1ROCK2GSK3BTGFBR1
SCHEMBL8797198 0.75 PTGS2 (0.63) PTGS2PTGS1
SCHEMBL7844008 0.74 PTGS2 (0.54) PTGS2PTGS1ROCK2GSK3BMAPK14
SCHEMBL6501123 0.72 PTGS2 (0.67) PTGS2PTGS1MAPK14KDM4E
SCHEMBL8297008 0.72 PTGS2 (0.65) PTGS2PTGS1
SCHEMBL7846478 0.72 PTGS2 (0.56) PTGS2PTGS1ROCK2GSK3BMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1499315-A1 COMBINATION OF CYCLOOXYGENASE-2 INHIBITORS AND THALIDOMIDE FOR THE TREATMENT OF NEOPLASIA Pharmacia Corporation (US) 2005-01-26 EP disclosed
WO-2003092691-A1 COMBINATION OF CYCLOOXYGENASE-2 INHIBITORS AND THALIDOMIDE FOR THE TREATMENT OF NEOPLASIA PHARMACIA COPORATION (US) 2003-11-13 WO disclosed